Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315620875> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4315620875 endingPage "383" @default.
- W4315620875 startingPage "377" @default.
- W4315620875 abstract "A 77-year-old man complaining of gross hematuria was referred to our hospital for further examination and treatment. The contrast-enhanced computed tomographic (CT) scan revealed a left ureteral tumor, multiple bladder tumors, para-aortic lymph node metastasis, left supraclavicular lymph node metastasis, multiple liver metastases, and multiple lung metastases. Transurethral resection was performed. One of the multiple bladder tumors, located at the bladder neck, was pathologically diagnosed as urothelial carcinoma, pT1, high grade, G2．We diagnosed the patient with metastatic ureteral cancer (T4N2M1, stage IV). We stated gemcitabine, cisplatin (GC) therapy, but stopped after the first course due to gemcitabine drug eruption. We changed the regimen to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) therapy and the cycle was completed without complications. However, CT scan showed disease progression. After palliative irradiation of the primary lesion, we administered pembrolizumab. Although he was asymptomatic, we diagnosed him with ocular myasthenia gravis because of a high level of serum anti-acetylcholine receptor antibodies and a temporary ptosis in his past history. In spite of the possibility of relapse of myasthenia gravis, treatment with pembrolizumab was continued with his consent since there were no other treatment options. After two courses of pembrolizumab, he was hospitalized due to disease progression and died about three weeks after admission. Myasthenia gravis is a possible immune-related adverse event of pembrolizumab, However, there have been few reports on the successful treatment with this agent in patients with previously diagnosed myasthenia gravis. We report, here, a case of metastatic ureteral carcinoma safely treated with pembrolizumab without relapse of ocular myasthenia gravis." @default.
- W4315620875 created "2023-01-12" @default.
- W4315620875 creator A5003192129 @default.
- W4315620875 creator A5004943277 @default.
- W4315620875 creator A5030933476 @default.
- W4315620875 creator A5037334342 @default.
- W4315620875 creator A5039271211 @default.
- W4315620875 creator A5049638243 @default.
- W4315620875 creator A5062947212 @default.
- W4315620875 creator A5084188104 @default.
- W4315620875 date "2022-12-01" @default.
- W4315620875 modified "2023-10-16" @default.
- W4315620875 title "[A Case of Metastatic Ureteral Cancer Treated with Pembrolizumab without Relapse of Ocular Myasthenia Gravis]." @default.
- W4315620875 doi "https://doi.org/10.14989/actauroljap_68_12_377" @default.
- W4315620875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36627771" @default.
- W4315620875 hasPublicationYear "2022" @default.
- W4315620875 type Work @default.
- W4315620875 citedByCount "0" @default.
- W4315620875 crossrefType "journal-article" @default.
- W4315620875 hasAuthorship W4315620875A5003192129 @default.
- W4315620875 hasAuthorship W4315620875A5004943277 @default.
- W4315620875 hasAuthorship W4315620875A5030933476 @default.
- W4315620875 hasAuthorship W4315620875A5037334342 @default.
- W4315620875 hasAuthorship W4315620875A5039271211 @default.
- W4315620875 hasAuthorship W4315620875A5049638243 @default.
- W4315620875 hasAuthorship W4315620875A5062947212 @default.
- W4315620875 hasAuthorship W4315620875A5084188104 @default.
- W4315620875 hasConcept C121608353 @default.
- W4315620875 hasConcept C126322002 @default.
- W4315620875 hasConcept C126838900 @default.
- W4315620875 hasConcept C141071460 @default.
- W4315620875 hasConcept C2776694085 @default.
- W4315620875 hasConcept C2777132456 @default.
- W4315620875 hasConcept C2777701055 @default.
- W4315620875 hasConcept C2778105408 @default.
- W4315620875 hasConcept C2780057760 @default.
- W4315620875 hasConcept C2780258809 @default.
- W4315620875 hasConcept C2781190966 @default.
- W4315620875 hasConcept C71924100 @default.
- W4315620875 hasConceptScore W4315620875C121608353 @default.
- W4315620875 hasConceptScore W4315620875C126322002 @default.
- W4315620875 hasConceptScore W4315620875C126838900 @default.
- W4315620875 hasConceptScore W4315620875C141071460 @default.
- W4315620875 hasConceptScore W4315620875C2776694085 @default.
- W4315620875 hasConceptScore W4315620875C2777132456 @default.
- W4315620875 hasConceptScore W4315620875C2777701055 @default.
- W4315620875 hasConceptScore W4315620875C2778105408 @default.
- W4315620875 hasConceptScore W4315620875C2780057760 @default.
- W4315620875 hasConceptScore W4315620875C2780258809 @default.
- W4315620875 hasConceptScore W4315620875C2781190966 @default.
- W4315620875 hasConceptScore W4315620875C71924100 @default.
- W4315620875 hasIssue "12" @default.
- W4315620875 hasLocation W43156208751 @default.
- W4315620875 hasOpenAccess W4315620875 @default.
- W4315620875 hasPrimaryLocation W43156208751 @default.
- W4315620875 hasRelatedWork W170791948 @default.
- W4315620875 hasRelatedWork W1995495011 @default.
- W4315620875 hasRelatedWork W2149633124 @default.
- W4315620875 hasRelatedWork W2186227808 @default.
- W4315620875 hasRelatedWork W2791377172 @default.
- W4315620875 hasRelatedWork W3046292530 @default.
- W4315620875 hasRelatedWork W3171157101 @default.
- W4315620875 hasRelatedWork W3208524222 @default.
- W4315620875 hasRelatedWork W4239089127 @default.
- W4315620875 hasRelatedWork W4247779517 @default.
- W4315620875 hasVolume "68" @default.
- W4315620875 isParatext "false" @default.
- W4315620875 isRetracted "false" @default.
- W4315620875 workType "article" @default.